GlassScriptPhysician profile
Samuel A Allen
NPI 1306861414
$287,429.94
in general payments reported to CMS, 2019-2025
31 companies · $43K in 2025
The $43K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $30K · 2021: $16K · 2022: $58K · 2023: $49K · 2024: $53K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Consulting Fee: $17K · Travel and Lodging: $14K · Food and Beverage: $8,434 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,738.00 |
| Consulting Fee | $16,560.00 |
| Travel and Lodging | $13,909.03 |
| Food and Beverage | $8,434.42 |
| Education | $268.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $188,236.88 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $42,259.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33,675.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $14,926.21 | 2023-2025 | Winrevair |
| Astrazeneca Pharmaceuticals LP | $2,971.64 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Medical Device Business Services, INC. | $1,919.96 | 2024 | Monarch |
| Glaxosmithkline, LLC. | $808.82 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Insmed, INC. | $443.55 | 2023-2025 | Arikayce, Brinsupri |
| Ethicon INC. | $366.54 | 2023-2025 | Monarch Platform |
| Genzyme Corporation | $347.65 | 2025 | |
| Verona Pharma, INC. | $312.82 | 2025 | Ohtuvayre |
| Intuitive Surgical, INC. | $143.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.17 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $111.36 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $83.45 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $69.52 | 2023 | Glassia |
| Electromed, INC. | $65.91 | 2025 | Smartvest |
| Gilead Sciences, INC. | $55.43 | 2019-2024 | |
| Pulmonx Corporation | $54.50 | 2024-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Mylan Specialty L.P. | $47.37 | 2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $42.35 | 2025 | Eliquis |
| Sunovion Pharmaceuticals INC. | $41.63 | 2019 | |
| Baxter Healthcare | $36.58 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Enterprises LLC | $22.56 | 2019 | |
| Circassia INC. | $17.55 | 2025 | Niox |
| Sandoz INC. | $16.59 | 2025 | Treprostinil |
| Shire North American Group INC | $15.48 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.